These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1224 related articles for article (PubMed ID: 16302732)

  • 1. Re-targeting of cytotoxic T lymphocytes and/or natural killer cells to CEA-expressing tumor cells with anti-CEA antibody activity.
    Kuroki M; Hachimine K; Huang J; Shibaguchi H; Kinugasa T; Maekawa S; Kuroki M
    Anticancer Res; 2005; 25(6A):3725-32. PubMed ID: 16302732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Strategies to endow cytotoxic T lymphocytes or natural killer cells with antibody activity against carcinoembryonic antigen.
    Kuroki M; Kuroki M; Shibaguchi H; Badran A; Hachimine K; Zhang J; Kinugasa T
    Tumour Biol; 2004; 25(4):208-16. PubMed ID: 15557759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human natural killer cell line modified with a chimeric immunoglobulin T-cell receptor gene leads to tumor growth inhibition in vivo.
    Schirrmann T; Pecher G
    Cancer Gene Ther; 2002 Apr; 9(4):390-8. PubMed ID: 11960290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting of T cells to CEA-expressing tumor cells by chimeric immune receptors with a highly specific single-chain anti-CEA activity.
    Arakawa F; Shibaguchi H; Xu Z; Kuroki M
    Anticancer Res; 2002; 22(6C):4285-9. PubMed ID: 12553071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel system for generating cytotoxic effector lymphocytes using carcinoembryonic antigen (CEA) peptide and cultured dendritic cells.
    Ohta K; Yamaguchi Y; Shimizu K; Miyahara E; Toge T
    Anticancer Res; 2002; 22(5):2597-606. PubMed ID: 12529970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Possible applications of antibodies or their genes in cancer therapy.
    Kuroki M; Huang J; Shibaguchi H; Tanaka T; Zhao J; Luo N; Hachimine K; Kinugasa T; Maekawa S; Enatsu S; Hamanaka W; Fukami T; Kuroki M
    Anticancer Res; 2006; 26(6A):4019-25. PubMed ID: 17195452
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen.
    Saha A; Chatterjee SK; Foon KA; Celis E; Bhattacharya-Chatterjee M
    Cancer Res; 2007 Mar; 67(6):2881-92. PubMed ID: 17363612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Active antiviral T-lymphocyte response can be redirected against tumor cells by antitumor antibody x MHC/viral peptide conjugates.
    Cesson V; Stirnemann K; Robert B; Luescher I; Filleron T; Corradin G; Mach JP; Donda A
    Clin Cancer Res; 2006 Dec; 12(24):7422-30. PubMed ID: 17189415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Carcinoembryonic antigen-immunoglobulin Fc fusion protein (CEA-Fc) for identification and activation of anti-CEA immunoglobulin-T-cell receptor-modified T cells, representative of a new class of Ig fusion proteins.
    Ma Q; DeMarte L; Wang Y; Stanners CP; Junghans RP
    Cancer Gene Ther; 2004 Apr; 11(4):297-306. PubMed ID: 15002034
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bypassing immunization: optimized design of "designer T cells" against carcinoembryonic antigen (CEA)-expressing tumors, and lack of suppression by soluble CEA.
    Nolan KF; Yun CO; Akamatsu Y; Murphy JC; Leung SO; Beecham EJ; Junghans RP
    Clin Cancer Res; 1999 Dec; 5(12):3928-41. PubMed ID: 10632322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NK cell receptors as tools in cancer immunotherapy.
    Sentman CL; Barber MA; Barber A; Zhang T
    Adv Cancer Res; 2006; 95():249-92. PubMed ID: 16860660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HLA-A*0201-restricted CEA-derived peptide CAP1 is not a suitable target for T-cell-based immunotherapy.
    Fauquembergue E; Toutirais O; Tougeron D; Drouet A; Le Gallo M; Desille M; Cabillic F; de La Pintière CT; Iero M; Rivoltini L; Baert-Desurmont S; Leprince J; Vaudry H; Sesboué R; Frébourg T; Latouche JB; Catros V
    J Immunother; 2010 May; 33(4):402-13. PubMed ID: 20386466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting and therapy of carcinoembryonic antigen-expressing tumors in transgenic mice with an antibody-interleukin 2 fusion protein.
    Xu X; Clarke P; Szalai G; Shively JE; Williams LE; Shyr Y; Shi E; Primus FJ
    Cancer Res; 2000 Aug; 60(16):4475-84. PubMed ID: 10969795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NK cell activating ligands on human malignant cells: molecular and functional defects and potential clinical relevance.
    Chang CC; Ferrone S
    Semin Cancer Biol; 2006 Oct; 16(5):383-92. PubMed ID: 16931041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Direct detection and quantitation of a distinct T-cell epitope derived from tumor-specific epithelial cell-associated mucin using human recombinant antibodies endowed with the antigen-specific, major histocompatibility complex-restricted specificity of T cells.
    Cohen CJ; Hoffmann N; Farago M; Hoogenboom HR; Eisenbach L; Reiter Y
    Cancer Res; 2002 Oct; 62(20):5835-44. PubMed ID: 12384546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting of cytotoxic cells against tumors with heterocrosslinked, bispecific antibodies.
    Segal DM; Qian JH; Garrido MA; Perez P; Winkler DF; Wunderlich JR; Snider DP; Valdayo MJ; Titus JA
    Princess Takamatsu Symp; 1988; 19():323-31. PubMed ID: 3269363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isolation and characterization of human recombinant antibodies endowed with the antigen-specific, major histocompatibility complex-restricted specificity of T cells directed toward the widely expressed tumor T-cell epitopes of the telomerase catalytic subunit.
    Lev A; Denkberg G; Cohen CJ; Tzukerman M; Skorecki KL; Chames P; Hoogenboom HR; Reiter Y
    Cancer Res; 2002 Jun; 62(11):3184-94. PubMed ID: 12036932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor defense by murine cytotoxic T cells specific for peptide bound to nonclassical MHC class I.
    Griffiths E; Ong H; Soloski MJ; Bachmann MF; Ohashi PS; Speiser DE
    Cancer Res; 1998 Oct; 58(20):4682-7. PubMed ID: 9788622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD8-interaction mutant HLA-Cw3 molecules protect porcine cells from human natural killer cell-mediated antibody-dependent cellular cytotoxicity without stimulating cytotoxic T lymphocytes.
    Sharland A; Lee JH; Saidman S; Waneck GL
    Transplantation; 2003 Dec; 76(11):1615-22. PubMed ID: 14702534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of human tumor-associated differentially expressed gene-12 (TADG-12/TMPRSS3)-specific cytotoxic T lymphocytes in human lymphocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian cancer.
    Bellone S; Anfossi S; O'Brien TJ; Cannon MJ; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
    Cancer; 2009 Feb; 115(4):800-11. PubMed ID: 19117353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 62.